Luca Benatti

Luca Benatti, a director since 2014, is the Chief Executive Officer and member of the Board of EryDel S.p.A. since 2012. He has over 25 years of experience in Pharma and Biotech. He was the co-founder and CEO of Newron Pharmaceuticals. Under his guidance, Newron developed a pipeline of innovative therapies including Xadago, approved worldwide for the treatment of Parkinson's disease. He is an independent Board member at Intercept Pharmaceuticals (ICPT, Nasdaq), Newron Pharmaceuticals, Metis Precision Medicine, Chairman of the Italian Angels for Biotech, and Member of the Strategic Advisory Board of Zambon, and Member of the Advisory Board of the Sofinnova-Telethon fund. He has authored several scientific publications and holds numerous patents. Luca Benatti is an Italian citizen. Lucas is a member of the R&D and the audit and risk committees.